VaxGen
Page Module:Infobox/styles.css has no content.Page Template:Infobox company/styles.css has no content.
| Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found. | |
Company type | Subsidiary |
|---|---|
| ISIN | Script error: No such module "WikidataIB". |
| Industry | Script error: No such module "WikidataIB". |
| Predecessor | Script error: No such module "WikidataIB". |
| Incorporated | Script error: No such module "WikidataIB". |
| Founded | Script error: No such module "WikidataIB". |
| Founder | Script error: No such module "WikidataIB". |
| Defunct | Script error: No such module "WikidataIB". |
| Fate | Operations shut down with parent company's bankruptcy |
| Successor | Script error: No such module "WikidataIB". |
| Headquarters | , United States |
| Revenue | Script error: No such module "WikidataIB". |
| Script error: No such module "WikidataIB". | |
| Script error: No such module "WikidataIB". | |
| Total assets | Script error: No such module "WikidataIB". |
Number of employees | Script error: No such module "WikidataIB". |
| Parent | diaDexus, Inc. (from 2010) |
| Website | Script error: No such module "WikidataIB". |
Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for deprecated parameters".
VaxGen was a biopharmaceutical company based in the San Francisco Bay Area.
Founded in 1995 and based in South San Francisco, California, the company was engaged in the development of vaccines that immunize against infectious disease, notably AIDS. On July 28, 2010, VaxGen Inc. was acquired by diaDexus, Inc. in a reverse merger transaction.;[1] diaDexus filed for bankruptcy in 2016.[2] VaxGen, Inc. does not have significant operations.
AIDSVAX
In the 1990s, VaxGen developed and began trials of an AIDS vaccine called AIDSVAX. The National Institute of Allergy and Infectious Diseases (NIAID) worked with Vaxgen when Vaxgen was developing its AIDS vaccine. Specifically, NIAID and Vaxgen worked together on research projects related to the body's immune response to the vaccine. As of 1998, according to NIAID, "The three-year study [of AIDSVAX] is the first large-scale trial of an HIV preventive vaccine, and will involve 5,000 volunteers at about 40 clinical sites in North America." Dr. Anthony Fauci said, "The effort to develop a safe and effective vaccine against HIV/AIDS is a global imperative and the highest priority of the NIH AIDS research program."[3]
However, in 2003, it was announced that the preliminary trials of the vaccine, conducted in Thailand and North America, had been unsuccessful.[4][5] The company's analysis of its results, which resulted in some potentially positive outcomes among patient subgroups, was criticized by statisticians as inappropriate.[6]
Anthrax vaccine
Vaxgen had focused its recent efforts on a new form of anthrax vaccine, for which it was awarded a $877 million contract to provide the vaccine under the Project Bioshield Act.[7]
In December 2006, the United States Department of Health and Human Services (HHS) unilaterally withdrew the $877 million contract, sending the stock tumbling as low as $1.20 per share.[citation needed]
References
Page Template:Reflist/styles.css has no content.
- ^ Page Module:Citation/CS1/styles.css has no content."VaxGen to Acquire diaDexus in a Stock-for-Stock Merger Under Revised Terms". Diadexus. Archived from the original on 2014-01-16. Retrieved 2014-01-14.
- ^ Area's diaDexus Files Chapter 7 Bankruptcy, Plans to Liquidate Assets, CFO to Step Down Immediately, Mark Terry, BioSpace.com published 14 June 2016[permanent dead link]
- ^ Page Module:Citation/CS1/styles.css has no content."NIAID Collaborates with VaxGen on Vaccine Studies" (Press release). National Institute of Allergy and Infectious Diseases. 18 August 1998. Retrieved 5 August 2014.
- ^ Page Module:Citation/CS1/styles.css has no content."BBC News article on the failure of the AIDSVAX trial". November 12, 2003. Retrieved January 6, 2010.
- ^ Page Module:Citation/CS1/styles.css has no content."Community Medical Research Institute Begins Inoculations in AIDSVAX Trial".
- ^ Page Module:Citation/CS1/styles.css has no content.Mitka, Mike (2003-03-26). "Critics Bash HIV Vaccine Trial Analysis". JAMA. 289 (12): 1491. doi:10.1001/jama.289.12.1491. ISSN 0098-7484.
- ^ Page Module:Citation/CS1/styles.css has no content.Williams, David (August 2, 2008). "Anthrax scientist Bruce Ivins stood to benefit from a panic". Los Angeles Times. Retrieved 2008-08-01.
Ivins is listed as a co-inventor on two patents for a genetically engineered anthrax vaccine, federal records show. Separately, Ivins also is listed as a co-inventor on an application to patent an additive for various biodefense vaccines.
External links
Historically was http://www.VaxGen.com. This URL is no longer for the Vaxgen, Inc. in this article.
Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal'). Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.
